您的位置: 首页 > 农业专利 > 详情页

PREDICTING RESPONSE TO A VEGF ANTAGONIST
专利权人:
Genentech; Inc.
发明人:
Yuanyuan XIAO,Carlos BAIS,YounJeong CHOI,Nicola C. CONSALVO
申请号:
US15581448
公开号:
US20170226198A1
申请日:
2017.04.28
申请国别(地区):
US
年份:
2017
代理人:
摘要:
The invention describes the use of high CD31 and/or tumor VEGFA as selection criteria for determining patient benefit or responsiveness to a VEGF antagonist, such as bevacizumab. The present invention also describes the use of high CD31 and/or tumor VEGFA as a selection criterion for treating cancer patients, such as ovarian cancer patients, who are undergoing a chemotherapy and/or anti-cancer therapy regimen, with a VEGF antagonist, such as bevacizumab.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充